Article

High conformal RT doses improve PSA, increase toxicity

Orlando, FL-Conformal radiotherapy to the prostate with isocenterdoses of 78 Gy lowers biochemical failure by at least 6% at 6 years, andby as much as 19% for men at higher risk of cancer relapse. But the costis a 14% increase in mild to moderate risk of rectal toxicity, accordingto two reports presented at the American Society of Clinical Oncology annualmeeting.

Related Videos
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
1 expert is featured in this series.
1 expert is featured in this series.
Drug costs | Image Credit: © pixelrobot - stock.adobe.com
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
blur image background of corridor in hospital or clinic image | Image Credit: @ whyframeshot - stock.adobe.com
April 18th 2025

U.S. News & World Report Names Michigan Institute of Urology’s Town Center ASC Among 2025 Best Ambulatory Surgery Centers

Michigan Institute of Urology
Ambulatory surgery centers were evaluated based entirely on objective, risk-adjusted measures of their patients’ outcomes.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Urologists perform first remote robot-assisted HIFU for prostate cancer
April 17th 2025

Urologists perform first remote robot-assisted HIFU for prostate cancer

Hannah Clarke
“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
April 17th 2025

Exploring new avenues in non–muscle invasive bladder cancer treatment

Urology Times staff
Three recent expert-led Clinical Forums explored current challenges and advancements in the management of non–muscle invasive bladder cancer.
Gene variant associated with increased risk of BPH
April 16th 2025

Gene variant associated with increased risk of BPH

Hannah Clarke
Data showed a significant association between the C allele of the SNP-765G>C of the PTGS2 gene and BPH.
© 2025 MJH Life Sciences

All rights reserved.